Table 2.
Patient ID | BCR-ABL1 % at diagnosis | BCR-ABL1 % at 3 mo | Sokal score | ELTS | BCR-ABL1 transcript type | TKIs | MMR by 12 mo | MR4.5 by 5 y | Withdrawal |
---|---|---|---|---|---|---|---|---|---|
EMR failure patients (n = 4) classified as low risk | |||||||||
145* | 55 | 14 | Int | Int | b2a2 | IM | N/A | N/A | Yes |
109 | 85 | 31 | High | High | b3a2 | IM, NIL | No | Yes | No |
102 | 124 | 13 | Low | Low | b3a2 | IM | Yes | No | No |
170 | 73 | 18 | Low | Low | b3a2 | IM, NIL | No | Yes | No |
EMR achievement patients (n = 2) classified as high risk | |||||||||
183 | 89 | 1.50 | Int | Int | b2a2 | IM, NIL | No | No | No |
159 | 86 | 6.90 | High | High | b3a2 | IM, NIL | No | No | No |
IM, imatinib; int, intermediate; N/A, not applicable; NIL, nilotinib.
Withdrawn at 6 months because of poor patient compliance.